RKDA 10-K Annual Report Dec. 31, 2023 | Alphaminr
Arcadia Biosciences, Inc.
ALPHAMINR

RKDA 10-K Fiscal year ended Dec. 31, 2023

Balance Sheet
Cash Flow
Income Statement
Debt
ARCADIA BIOSCIENCES, INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-K
Fiscal year ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
PROXIES
DEF 14A
Filed on Dec. 19, 2025
DEF 14A
Filed on May 16, 2024
DEF 14A
Filed on April 25, 2023
DEF 14A
Filed on Feb. 15, 2023
DEF 14A
Filed on Jan. 6, 2023
DEF 14A
Filed on June 1, 2022
DEF 14A
Filed on April 19, 2022
DEF 14A
Filed on April 20, 2021
DEF 14A
Filed on April 17, 2020
DEF 14A
Filed on April 18, 2019
DEF 14A
Filed on May 17, 2018
DEF 14A
Filed on April 13, 2018
DEF 14A
Filed on Dec. 27, 2017
DEF 14A
Filed on April 26, 2017
DEF 14A
Filed on April 22, 2016
CIK: 1469443
Filing Type: 10-K/A
Report Date: 2023-12-31
Download URL: https://www.sec.gov/Archives/edgar/data/1469443/000095017024049710/rkda-20231231.htm
]]>
TABLE OF CONTENTS
Part IItem 1. BusinessItem 1A. Risk FactorsItem 1A. RisItem 1B. Unresolved Staff CommentsItem 1B. UnresolveItem 1C. CybersecurityItem 2. PropertiesItem 2. PrItem 3. Legal ProceedingsItem 3. LegalItem 4. Mine Safety DisclosuresItem 4. Mine SafPart IIItem 5. Market For Registrant S Common Equity, Related Stockholder Matters and Issuer Purchases Of Equity SecuritiesItem 5. Market For Registrant S Common Equity, Related StocItem 6. [reserved]Item 7. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 7. Management S Discussion and Analysis OfItem 7A. Quantitative and Qualitative Disclosures About Market RiskItem 7A. Quantitative and QualitatItem 8. Financial Statements and Supplementary DataItem 8. Financial StatementNote 1. Description Of BusinessNote 2. Summary Of Significant Accounting PoliciesNote 3. Recent Accounting PronouncementsNote 4. InventoryNote 5. Property and Equipment, NetNote 6. Investments and Fair Value InstrumentsNote 7. Consolidated Joint VentureNote 8. Accounts Payable and Accrued ExpensesNote 9. Collaborative ArrangementsNote 10. Equity FinancingNote 11. Warrants and OptionsNote 12. Stock-based Compensation and Employee Stock Purchase ProgramNote 13. Commitments and ContingenciesNote 14. LeasesNote 15. Income TaxesNote 16. Retirement BenefitsNote 17. Segment and Geographic InformationNote 18. Net Loss Per ShareNote 19. Related Party TransactionsNote 20. Subsequent EventsItem 9. Changes in and Disagreements with Accountants on Accounting and Financial DisclosureItem 9. Changes in and Disagreements with AccouItem 9A. Controls and ProceduresItem 9A. ControlsItem 9B. Other InformationItem 9B. OtherItem 9C. Disclosure Regarding Foreign Jurisdictions That Prevent InspectionsPart IIIItem 10. Directors, Executive Officers and Corporate GovernanceItem 10. Directors, Executive OffItem 11. Executive CompensationItem 11. ExecutiItem 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder MattersItem 12. Security Ownership Of Certain Beneficial OwnItem 13. Certain Relationships and Related Transactions, and Director IndependenceItem 13. Certain Relationships and RelatedItem 14. Principal Accounting Fees and ServicesItem 14. Principal AccounPart IVItem 15. Exhibits, Financial Statement SchedulesItem 15. Exhibits, FinancItem 16. Form 10-k SummaryItem 16. Form

Exhibits

3.1 Amended and Restated Certificate of Incorporation of Registrant. 8-K 001-37383 3.1 5/26/2015 3.2 Amendment to the Amended and Restated Certificate of Incorporation of Registrant. 8-K 001-37383 3.1 2/28/2023 3.3 Certificate of Designation of Series A Preferred Stock. 8-K 001-37383 3.1 12/8/2022 3.4 Amended and Restated Bylaws of Registrant. 8-K 001-37383 3.2 5/26/2015 3.5 Amendment to the Amended and Restated Bylaws of Registrant. 8-K 001-37383 3.2 12/8/2022 4.1 Form of Registrants common stock certificate. S-3 333-224061 4.1 3/30/2018 4.2 Form of Common Stock Purchase Warrant. 8-K 001-37383 4.1 3/23/2018 4.3 Form of Common Stock Purchase Warrant. 8-K 001-37383 4.1 6/14/2019 4.4 Form of Placement Agent Warrant. 8-K 001-37383 4.2 6/14/2019 4.5 Form of Common Stock Purchase Warrant. 8-K 001-37383 4.1 9/9/2019 4.6 Form of Placement Agent Warrant. 8-K 001-37383 4.2 9/9/2019 4.7 Description of Registrants Securities Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. 4.8 Form of Common Stock Purchase Warrant. 8-K 001-37383 4.1 5/18/2020 4.9 Form of Placement Agent Warrant. 8-K 001-37383 4.2 5/18/2020 4.10 Form of Common Stock Purchase Warrant. 8-K 001-37383 4.1 7/8/2020 4.11 Form of Placement Agent Warrant. 8-K 001-37383 4.2 7/8/2020 4.12 Form of Investor Warrant. 8-K 001-37383 4.1 12/22/2020 4.13 Form of Placement Agent Warrant. 8-K 001-37383 4.2 12/22/2020 4.14 Form of Investor Warrant. 8-K 001-37383 4.1 1/29/2021 4.15 Form of Placement Agent Warrant. 8-K 001-37383 4.2 1/29/2021 4.16 Form of Investor Pre-Funded Warrant. 8-K 001-37383 4.1 8/16/2022 4.17 Form of Investor Preferred Investment Option. 8-K 001-37383 4.2 8/16/2022 4.18 Form of Placement Agent Preferred Investment Option. 8-K 001-37383 4.3 8/16/2022 4.19 Form of Pre-Funded Warrant. 8-K 001-37383 4.1 3/3/2023 4.20 Form of Series A Preferred Investment Option. 8-K 001-37383 4.2 3/3/2023 4.21 Form of Series B Preferred Investment Option. 8-K 001-37383 4.3 3/3/2023 4.22 Form of Placement Agent Preferred Investment Option. 8-K 001-37383 4.4 3/3/2023 10.1* Form of Indemnification Agreement between the Registrant and each of its Officers and Directors. S-1 333-202124 10.7 2/17/2015 10.2* 2006 Stock Plan, as amended and restated, and form of agreement thereunder. S-1 333-202124 10.8 2/17/2015 10.3* 2015 Omnibus Equity Incentive Plan and forms of agreement thereunder. S-1 333-232858 10.9 7/26/2019 10.4* 2015 Employee Stock Purchase Plan and form of agreement thereunder. S-1/A 333-202124 10.10 5/11/2015 10.5* Executive Incentive Bonus Plan. S-1/A 333-202124 10.15 5/11/2015 10.6* Amended and Restated Director Compensation Policy. 10-Q 001-37383 10.14 5/10/2016 10.7* Form of Severance and Change in Control Agreement. S-1/A 333-202124 10.18 4/6/2015 10.8 Base Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP, including Amendments 1-7. S-1 333-229047 10.16 12/27/2018 10.9 Amendment No. 8 to the Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP. 10-Q 001-37383 10.8 5/13/2020 10.10 Amendment No. 9 to the Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP. 10-Q 001-37383 10.2 8/13/2020 10.11* Employment Letter for Stanley E. Jacot Jr., Chief Executive Officer. 10-Q 001-37383 10.1 5/12/2022 10.12* Severance and Change in Control Agreement for Stanley E. Jacot, Jr. 10-Q 001-37383 10.1 5/12/2022 10.13* Inducement Option Grant for Stanley E. Jacot, Jr. 10-Q 001-37383 10.2 5/12/2022 10.14* Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer. 8-K/A 001-37383 10.1 1/5/2023 10.15+ Limited Liability Company Operating Agreement for Archipelago Ventures Hawaii, LLC, dated as of August 9, 2019. 8-K 001-37383 10.1 8/9/2019 10.16 Securities Purchase Agreement dated as of March 19, 2018, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. 8-K 001-37383 10.1 3/23/2018 10.17 Form of Registration Rights Agreement. 8-K 001-37383 10.2 3/23/2018 10.18 Form of Securities Purchase Agreement dated as of June 11, 2018, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. 8-K 001-37383 10.1 6/14/2018 10.19 Form of Securities Purchase Agreement dated as of June 12, 2019, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. 8-K 001-37383 10.1 6/14/2019 10.20 Form of Securities Purchase Agreement dated as of September 5, 2019, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. 8-K 001-37383 10.1 9/9/2019 10.21 Form of Letter Agreement, dated as of May 14, 2020. 8-K 001-37383 10.1 5/18/2020 10.22 Form of Letter Agreement, dated as of July 6, 2020. 8-K 001-37383 10.1 7/8/2020 10.23 Form of Securities Purchase Agreement dated as of December 18, 2020, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.1 12/22/2020 10.24 Form of Securities Purchase Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.1 1/29/2021 10.25 Form of Registration Rights Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.2 1/29/2021 10.26 Form of Securities Purchase Agreement, dated as of August 12, 2022, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.1 8/16/2022 10.27 Form of Securities Purchase Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.1 3/3/2023 10.28 Form of Registration Rights Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. 8-K 001-37383 10.2 3/3/2023 10.29 Form of Investment Option Amendment, dated as of March 2, 2023. 8-K 001-37383 10.3 3/3/2023 10.30+ Master Transaction Agreement. 8-K 001-37383 10.2 12/22/2020 10.31+ Asset Purchase Agreement dated May 17, 2021, by and among Arcadia, Buyer, Seller, Eko, Lief, Zola and Parent. 8-K 001-37383 10.1 5/21/2021 21.1 List of subsidiaries of the Registrant. S-1 333-262407 21.1 1/28/2022 23.1 Consent of Deloitte & Touche LLP, independent registered public accounting firm. 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, 32.1 Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 97.1 Dodd-Frank Clawback Policy.